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NF-κB factors are cardinal transcriptional regulators of inflammation and apoptosis,
involved in the brain programing of systemic aging and in brain damage. The composition
of NF-κB active dimers and epigenetic mechanisms modulating histone acetylation,
finely condition neuronal resilience to brain insults. In stroke models, the activation of
NF-κB/c-Rel promotes neuroprotective effects by transcription of specific anti-apoptotic
genes. Conversely, aberrant activation of NF-κB/RelA showing reduced level of total
acetylation, but site-specific acetylation on lysine 310, triggers the expression of pro-
apoptotic genes. Constitutive knockout of c-Rel shatters the resilience of substantia nigra
(SN) dopaminergic (DA) neurons to aging and induces a parkinsonian like pathology
in mice. c-rel /  mice show increased level of aberrantly acetylated RelA in the basal
ganglia, neuroinflammation, accumulation of alpha-synuclein, and iron. Moreover, they
develop motor deficits responsive to L-DOPA treatment and associated with loss of DA
neurons in the SN. Here, we discuss the effect of unbalanced activation of RelA and c-Rel
during aging and propose novel challenges for the development of therapeutic strategies
in neurodegenerative diseases.
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Introduction
In the central nervous system, NF-κB transcription factor acts as a pleiotropic regulator of target
genes controlling physiological function (1) as well as pathological processes associated with
neurodegeneration (2, 3).
The NF-κB family of transcription factors is composed by five different members that are p65
(RelA), RelB, c-Rel, p50/p105 (NF-κB1), and p52/p100 (NF-κB2). The RelA subunit, composing
the activated p50/RelA dimer, and its post-transcriptional modifications play a pivotal role in the
onset of neurodegenerative processes triggered by ischemic insults as well as glutamate or beta-
amyloid toxicity (4–8). The c-Rel subunit within activated NF-κB dimers counteracts the ischemic
injury acting as an innate mechanism of neuroprotection (9). The c-Rel factor is reduced in neurons
exposed to oxygen–glucose deprivation (OGD), and its over-expression can limit the cell death.
Abbreviations: 1B/DMT1, 1B isoform of divalent metal transporter-1; AMPK, AMP-activated kinase; BDNF, brain-derived
neurotrophic factor; BIRC3, baculoviral IAP repeat-containing protein 3; DA, dopaminergic; HAT, histone acetyltransferase;
HDAC, histone deacetylase; K310, lysine 310; MCAO, middle cerebral artery occlusion; MnSOD, superoxide dismutase;
MPP+, 1-methyl-4-phenylpyridinium; NAD+, nicotinamide adenosine dinucleotide; OGD, oxygen–glucose deprivation; PD,
Parkinson’s disease; RIP1, receptor interacting protein; ROS, reactive oxygen species; SIRT1, sirtuin 1; SN, substantia nigra;
SNc, SN pars compacta; TH, tyrosine hydroxylase; TNF, tumor necrosis factor; UCP4, mitochondrial uncoupling protein 4.
Frontiers in Neurology | www.frontiersin.org May 2015 | Volume 6 | Article 981
Lanzillotta et al. NF-κB in innate neuroprotection
Moreover, the deficiency of c-Rel induces an age-related behav-
ioral parkinsonism inmice, with degeneration of nigral dopamin-
ergic (DA) neurons and development of a Parkinson’s disease
(PD)-like neuropathology (10). Recent evidence has shown that
activation of NF-κB drives the systemic and brain aging process
inmice (11, 12). Notably, Tilstra and colleagues demonstrated that
RelA is the most contributing subunit in degenerative changes
associated with senescence in a progeroid mice model (13).
We propose that while RelA activation accompanies nor-
mal brain aging, a misbalance between RelA and c-Rel might
drive pathological aging by affecting the survival of substantia
nigra (SN) DA cell and turning old mice into a parkinsonian
phenotype.
RelA and c-Rel: Two Opposing Regulators
of Neuronal Resilience to Brain Ischemia
In the central nervous system, NF-κB factors are key players of
a number of physiological processes such as neurogenesis (14),
neuritogenesis (15), synaptic plasticity, learning, and memory
(16–18). In recent years, a body of data has shown that NF-κB
dysregulation participates to neurodegenerative mechanisms that
occur in brain exposed to trauma or ischemia (19, 20), as well as
in the brain of patients affected by PD (21, 22) and Alzheimer’s
disease (23).
The neuronal response to external stimuli relies on a differential
activation ofNF-κBdimers.We found that targeting RelA or c-Rel
expression by antisense oligonucleotides (5) or siRNAs (6, 9) pro-
duces opposite effects on neuron survival. While over-activated
p50/RelA dimers contribute to the apoptotic program, the c-Rel
containing dimers increase the resilience of injured neuronal cells
(Figure 1). Neurotoxic stimuli, such as ischemia (4, 9), glutamate
(5), β-amyloid (7, 24), or 1-methyl-4-phenylpyridinium (MPP+)
(25, 26), induce p50/RelA dimers activation and the transcrip-
tion of a panel of pro-apoptotic genes (4). Conversely, c-Rel-
containing dimers are responsible for anti-apoptotic gene expres-
sion by signals promoting neuroprotection in diverse neurotoxic
settings, such as S100B in models of NMDA-mediated excito-
toxicity (27), agonists at mGlu5 receptors against β-amyloid- (7)
and MPP+ toxicity (25) or adipocyte-derived hormone leptin
in neurons exposed to OGD (28). Over-expression of c-Rel in
cultured neurons promotes anti-apoptotic effects by inducing the
transcription of manganese superoxide dismutase (MnSOD) and
Bcl-xL (7, 29, 30). c-Rel overabundance also limits the generation
FIGURE 1 | The p50/RelA and p50/c-Rel dimers regulate neuronal
survival. Anti-apoptotic effects of NF-κB can be mediated by c-Rel containing
dimers, which enhance neuronal resilience to oxidative stress by inducing
Bcl-xL, MnSOD, UCP4, and BIRC3 expression. NF-κB anti-apoptotic effects
can also be mediated by p50/RelA during preconditioning ischemia through the
transcription of Bcl-xL. The pro-apoptotic effect elicited by NF-κB p50/RelA
dimer in noxious ischemia is dependent on changes in the RelA acetylation
state. A lower grade of RelA general acetylation, respect to control condition,
but a site-specific acetylation on Lys 310 residue addresses the NF-κB binding
toward Bim, Noxa, and DMT1 promoter.
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of reactive oxygen species (ROS) by inducing transcription of
the mitochondrial uncoupling proteins 4 (UCP4) (31), a brain-
specific mitochondrial ion channel producing mild reduction
of mitochondrial membrane potential and neuroprotection (32).
Moreover, c-Rel can control the expression of baculoviral IAP
repeat-containing protein 3 (BIRC3), named also as cIAP2, an
anti-apoptotic E3 ligase, which can modulate the receptor inter-
acting protein 1 (RIP1) activity by ubiquitination (33). Depending
on its ubiquitination status, RIP1 can dictates if tumor necro-
sis factor (TNF)-α induces cell survival (and inflammation), or
cell death pathways (34). Ubiquitinated RIP1 can recruit other
kinases and finally induce NF-κB-mediated transcription of pro-
survival and pro-inflammatory genes (TNF-α-dependent NF-κB
activation) (35).
The elucidation of the dual effects of NF-κB activation on
neuron survival was more evident in studies of severe brain
ischemia. The activation of p50/RelA rapidly occurs in neurons
and glial cells and has been implicated in pathogenesis of post-
ischemic injury (36–38). In brain ischemic tissue ofmice subjected
to permanent middle cerebral artery occlusion (MCAO) and in
primary cortical neurons exposed to OGD, NF-κB followed a
similar pattern of activation (8, 39) characterized by increased
nuclear translocation of p50/RelA dimer (4, 36) and decreased
translocation of c-Rel-containing dimers (9). In these conditions,
NF-κB activity was associated with an unbalance expression of
pro-apoptotic RelA target genes, i.e., an increased expression
of the pro-apoptotic members of Bcl-2 family genes (4) and
reduced level of the anti-apoptotic member Bcl-xL (9, 40). During
brain ischemia, RelA induced the expression of the 1B isoform
of the divalent metal transporter-1 (1B/DMT1), the membrane
carrier responsible for iron accumulation and brain damage after
injury (41). The RelA-induced 1B/DMT1 expression acted as
an upstream mechanism responsible for iron accumulation and
contributing to neuronal cell death. While the over-expression of
RelA increased cell death, the over-expression of c-Rel prevented
neuronal loss in cortical neurons exposed to OGD, by increas-
ing the transcription of Bcl-xL gene (9, 39). Knocking-down
c-Rel expression exacerbated neuronal susceptibility to OGD-
mediated damage. Under brain ischemia, mice deficient for the
c-Rel factor appeared insensitive to neuroprotective activity of
leptin, a c-Rel inducer capable to limit cortical damage in wild-
type mice (24, 28). These data strongly suggested that inhibi-
tion of c-Rel-containing dimers and activation of p50/RelA are
key events in the pathogenesis of post-ischemic brain injury. In
spite of these premises, p50/RelA activation per se appeared to
be insufficient to drive pro-apoptotic transcription during brain
ischemia. A similar pattern of p50/RelA nuclear translocation was
found in mice exposed to a brief preconditioning ischemia (8)
generating brain tolerance to a subsequent lethal ischemic injury
(42). In neuronal cells, likewise in tumor cells, gene targeting
by p50/RelA is finely regulated by post-transcriptional modifi-
cation of RelA subunit, such as phosphorylation and acetylation
(43). These modifications shape the strength and specificity of
the NF-κB–DNA binding and final transcriptional responses. On
this line, we investigated whether the activation of the p50/RelA
dimer, in preconditioning or in lethal ischemia, differs in the RelA
acetylation state (44).
RelA Acetylation is a Dynamic Process
Which Tunes p50/RelA-Mediated
Pro-Apoptotic Transcription in Brain
Ischemia and is Modulated by Epigenetic
Drugs
Acetylation is the key post-translational modification of histones
that controls the accessibility of chromatin to the transcriptional
machinery and plays an essential role in gene activation (45).
Lysine acetylation is reversible and controlled by the opposing
activities of histone acetyltransferase (HAT) and histone deacety-
lase (HDAC).
Besides histones, diverse non-histone proteins, including tran-
scription factors NF-κB, are modified by HAT co-activators and
HDACs (46). Acetylation of RelA on specific lysine residues
(K122, 123, 218, 221, and 310) is a dynamic process that differently
affects the RelA interaction with IκBα, the DNA-binding ability
and the transcriptional activity of the protein (43, 47).
Members of class I HDACs, particularly HDAC1, HDAC2, and
HDAC3, inhibited by vorinostat and entinostat (MS-275) are the
most responsible for the general deacetylation of RelA (43, 48).
Conversely, sirtuin 1 (SIRT1), an atypical class III HDAC that
requires nicotinamide adenosine dinucleotide (NAD+) rather
than zinc as a co-factor (49), activated by resveratrol, selectively
deacetylates RelA at lysine 310 (K310) residue (8, 50).
Our studies have shown that mechanisms affecting the acety-
lation state of RelA might discriminate between protective and
neurotoxic activation of NF-κB during ischemia (8). Protective
ischemic preconditioning and harmful ischemia induced simi-
lar levels of p50/RelA activation, but only the ischemic injury
induced an atypical RelA acetylation. The RelA that translocated
to the nucleus in primary cortical neurons exposed to precondi-
tioning OGD, or in cortices of mice subjected to precondition-
ing MCAO, showed a general deacetylation that paralleled the
deacetylation on the K310 residue. Conversely, RelA activated in
neurons exposed to lethal OGD or in cortices of mice subjected
to noxious ischemia displayed a general deacetylation, but site-
specific acetylation on the K310 residue. This suggested that a
mismatch between general and “site-specific” (K310) acetylation
of RelA – where total acetylation decreases and K310 acetylation
increases – could be responsible for pro-apoptotic transcription
in ischemic conditions (8). The relevance of K310 acetylation
to RelA-mediated effects during ischemia was demonstrated by
mutagenesis analysis. The substitution of lysine with arginine
at the RelA 310 residue impaired the acetylation at this site. In
cells expressing the mutated RelA subunit, the OGD-mediated
DMT1 transcription and the cell damage were totally prevented
(8, 41). By undergoing such aberrant acetylation, RelA detached
from the anti-apoptoticBcl-xL promoter to bind the pro-apoptotic
Bim promoter (44). In addition to changing the acetylation state
of RelA, lethal ischemia produced a significant reduction of H3
histone acetylation (44), in line with previous evidence (51).
Prompted by these findings and in order to correct altered
acetylation of RelA and histones after brain ischemia, we studied
the association of the specific class IHDAC inhibitorMS-275 (52),
and resveratrol (53). MS-275 is a synthetic benzamide derivative
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that currently is under clinical evaluation for cancer therapy (54).
MS-275 has been shown to inhibit HDAC 1-3 with excellent
pharmacokinetic properties (52).
Resveratrol is a polyphenol with multiple activities, including
anti-oxidant, anti-tumorigenic, and neuroprotective activity (53,
55). In various models of brain ischemia, resveratrol delayed
axonal degeneration after injury and mitigated the formation of
free radical species as well as mitochondria-mediated apoptosis
(56–59).
Widely known mechanisms of resveratrol action include the
activation of the longevity factors SIRT1 (60) and AMP-activated
kinase (AMPK), a serine–threonine kinase that acts as a key
metabolic and stress sensor/effector (61). We found that treat-
ments with either MS-275 or resveratrol in the post-ischemic
period of mice subjected to MCAO decreased the infarct volume
and displayed a significant neuroprotective activity in cortical
neurons exposed to OGD (44). What’s more, we showed that the
combination of MS-275 and resveratrol at sub-threshold doses
elicited a synergistic effect leading to maximal neuroprotection in
both the animal and the cellularmodels of brain ischemia.MS-275
at the highest concentration tested, 1µM, increased acetylation
of H3 histones on K9/18 residues in neurons exposed to OGD.
Resveratrol, unable to modify per se the H3 acetylation, produced
a synergistic acetylation of H3 K9/18 when used in combination
with MS-275.
Notably, the synergistic effect produced by co-administration
of low doses of MS-275 (0, 1µM) and resveratrol (3µM) was sus-
tained by AMPK activation by resveratrol. This could be ascribed
to the fact that AMPK can activate many catabolic pathways to
produce ATP and acetyl-CoA (62), the fundamental co-factor for
HAT activity. AMPK has also been found to indirectly support
the resveratrol-dependent SIRT1 induction by inducing NAD+
generation (61). As a consequence of AMPK-mediated enhance-
ment of HAT and SIRT1 activity, the combination of MS-275
and resveratrol reversed the mismatch of RelA acetylation state
in neurons exposed to OGD by, respectively, enhancing the RelA
general acetylation and by reducing the acetylation at the K310
residue. The neuroprotective effect and transcription of anti-
apoptotic genes observed following the treatment with the drug
combination appeared closely related to the restored optimal RelA
acetylation state (8, 63). The protective and transcriptional effects
produced by resveratrol and MS-275 in cortical neurons were
entirely reproduced in themouseMCAOmodel. The combination
of sub-threshold doses of the drugs, administered during the
reperfusion period, elicited a synergistic effect that limited the
cerebral infarct volume and the subsequent neurological deficits.
MS-275 and resveratrol in combination showed a long-lasting
efficacy as the beneficial effects were still evident 72 h after the
injury. Moreover, they displayed a wide therapeutic window as
their efficacy was evident when administered within 7 h after the
ischemic onset. The treatment induced a transcriptional switch
from pro- to anti-apoptotic genes. The RelA binding shifted from
the Bim to the Bcl-xL promoter and the acetylation of associated
histones changed accordingly. H3 acetylation decreased at theBim
and increased at the Bcl-xL gene.
Recently, we evaluated the acetylation of histone residues at
the brain-derived neurotrophic factor (BDNF) IV promoter in
primarymouse cortical neurons exposed toOGDand treatedwith
the synergistic combination of MS-275 and resveratrol (64).
We focused on promoter IV, which is known to be important
for synaptic plasticity, both during neuronal development and in
the adult brain (65). In the cortex, the promoter IV-dependent
BDNF transcription accounts for the majority of the neuronal
activity-induced BDNF expression (66, 67). Several studies have
proposed BDNF as possible mediators of the beneficial effects of
HDAC inhibitors in nervous system disorders (68–70). A ChIP
analysis in cortical neurons showed that histones at the BDNF
promoter IV were deacetylated after OGD exposure. Treatment in
the post-OGDperiodwith the combination ofMS-275 and resver-
atrol significantly increased acetylation at H3K9/18 and H4K12
histones (64). These histone modifications may act cooperatively
and possibly in parallel to other histone modifications to increase
BDNF expression.
It can be proposed that neuroprotection elicited by MS-275
and resveratrol treatment is also closely related to modulation
of BDNF expression and may improve neurologic function by
enhancing neuronal plasticity.
All together, these data provide evidence that a pharmacolog-
ical intervention targeting the epigenetic machinery can repre-
sents a promising strategy to limit post-ischemic injury with an
extended therapeutic window.
c-Rel Deficiency Causes a Progressive
Late-Onset Parkinsonism in Mice
Following the evidence that RelA and c-Rel play opposing effects
on neuron survival, and prevalence of p50/RelA activation versus
p50/c-Rel triggers apoptotic cell death in brain ischemia (9), we
tested whether a constitutive defect in c-Rel protein might affect
the brain aging. Behavioral and pathological analyses of c-Rel
knockout mice were performed at 2, 12, and 18months of age
and c-rel /  mice showed to develop a PD-like syndrome and
pathology with aging (10). Besides c-Rel subunit, other NF-κB
subunits have been previously investigated for possible correlation
with the onset of a parkinsonian pathology. Increased levels of
RelA have been detected in the brains of MPTP-intoxicated mice
(21) as well as in the brain of subjects affected by PD (21, 22,
71). This increase was evident both in neuronal and glial cells of
the SN, suggesting a role of RelA activation in neuronal cell loss
and neuroinflammatory response associatedwith PDprogression.
The role of the other NF-κB subunits in PD remains unclear. The
p50 /  mice treated with MPTP did not behave differently from
wild-type mice (72), suggesting no, or only minor, role for p50 in
the regulation of SN neuron resilience.
In 18-month-old c-rel / mice, the analysis of tyrosine hydrox-
ylase (TH)-positive cells of the SN pars compacta (SNc) revealed
a loss of DA neurons that paralleled the total loss of Nissl-stained
cells. No significant change in the estimated number of DA cells
was evident in 2- or 12-month-old c-rel /  mice compared to
age-matched controls. Notably, the loss of SNc DA neurons was
associated with a decrease of TH-positive fibers and reduction
of dopamine transporter (DAT) and dopamine content in the
striatum. The 18-month-old c-rel /  mice displayed no signifi-
cant degeneration in the other brain areas examined, the nucleus
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basalis magnocellularis and the medial septal area, or in the
ventral tegmental area that is generally spared in PD. Additional
examination of SNc in aged c-rel /  mice revealed a marked
immunoreactivity for α-synuclein, the main protein constituent
of Lewy bodies and Lewy neuritis and the key pathological feature
of PD (73). Of note, fibrillary aggregated α-synuclein, detected
by Thioflavin-S labeling, was present in the spared DA neu-
rons of the SNc. Accumulation of insoluble α-synuclein in the
mesencephalon was confirmed by the presence of a monomeric
α-synuclein in the urea/SDS extracts used to solubilize the
insoluble fraction. Neuroinflammation characterized by chronic
microglial reactivity, RelA activation, and iron accumulation are
also important features of the PD neuropathology (74, 75). As
observed in PDbrain (76), SNc and striatumof aged c-rel / mice
showedmarked signs of microglia activation with increased num-
ber, swollen cell bodies, and thick processes of CD11b-positive
cells. Both SNc and striatum of aged c-rel /  mice displayed
elevated levels of iron and increase of the iron transporter DMT1
that, as mentioned above, is a transcriptional target of aberrantly
acetylated RelA. Preliminary investigation on NF-κB in striatal
extracts of 18-month-old c-rel /  mice confirmed, indeed, the
presence of aberrantly acetylated RelA as reported in Figure 2.
The immunoprecipitated RelA showed reduced level of general
acetylation associated with increased site-specific acetylation at
the K310 residue. These changes occurred without any significant
variation in the cellular amount of RelA. This finding strongly
FIGURE 2 | RelA acetylation in the striatum of c-rel /  and wt mice.
(A) Representative picture of the immunoprecipitation analysis of RelA
acetylation in total proteins of caudatus putamen. RelA acetylation at K310
residue increased, while total RelA acetylation was reduced in striatal total
extracts of 18-month-old c-rel /  mice. No significant change was detected
in the total RelA content. (B) Values from densitometry analysis of
immunoblots are expressed as a percentage of the wt value. The signal given
by IgG(H) is used as a control for the quality of the immunoprecipitation. Bars
depict the meanSEM (n= 4 animals per group), *p<0.01 versus wt value.
suggests that amisbalance between c-Rel andRelA can evolve dur-
ing aging in c-rel / mice to produce changes in RelA acetylation,
microglia activation, and neuronal apoptosis.
Because inflammatory and neurotoxic activation of microglia
have been also reported to be triggered by acetyl-RelA (K310)
(77), it is feasible that microglia activation participate to the
neurodegenerative process in c-rel /  mice. The extensive
analysis of the neuroinflammatory profile of c-rel /  mice
along with disease progression will reveal the exact entity of this
inflammatory process and the specific participation of innate and
adaptive immunity.
The neurochemical changes observed in aged c-rel /  mice
were also accompanied by the onset ofmotor deficits. A significant
impairment in spontaneousmotor activity was evident in c-rel / 
mice at 18months, but not in younger mice as previously shown
(17, 18). Indeed, either monitored for 1 h or six consecutive days
to avoid stress-related bias, 18-month-old c-rel / mice displayed
a lower locomotor activity. Furthermore, the gaiting analysis sup-
ported the presence of a locomotor dysfunction related to bradyki-
nesia and rigidity. Noteworthy, the treatment with -DOPA plus
benserazide, a cocktail that is considered the gold standard for PD
therapy, totally reversed the locomotor deficits and normalized
most of the gaiting parameters.
Despite these findings, how the constitutive c-Rel deficiency
can specifically affect DA neurons of SNc is still an open ques-
tion (10). The selective vulnerability of SNc neurons in PD has
been attributed to the peculiar “energy-demanding” physiology of
these cells (78), which display enormous axonal field and impres-
sive number of synapses for each axon (79). Moreover, during
their pacemaking activity, SNc DA neurons, but not the ventral
tegmental area neurons, generate autonomous action potentials
by unusual engaging of L-type Ca2+ channels, which require sub-
sequent activation of ATP-dependent Ca2+ pumps to maintain
Ca2+ homeostasis (80). The energy production by mitochondria
and endoplasmic reticulum in SNcDAneurons associates with the
generation of large amounts of ROS that are constantly neutralized
by anti-oxidant systems, including SODs catalases, glutathione
peroxidase, and UCP4 and UCP5 (81). It can be inferred that
in the absence of c-Rel a reduced expression of UCP4 (31) and
MnSOD (7, 29)might enhance ROS accumulation during aging in
SNc neurons (82), and synergize with reduced expression of anti-
apoptotic Bcl-xL (9, 30) to affect neuronal resilience. Also, it is
conceivable that mitochondria impairment associated with c-Rel
deficiency may switch the acetylation state of RelA during aging
to elevate Bim, DMT1, and iron (75) as well as the intracellular
levels ofα-synuclein (83). In turn, these events lead toα-synuclein
aggregation (83), microglia activation, and neuronal damage (84).
All together, these findings point to a role of c-Rel in the regulation
of SNc susceptibility to aging.
Finally, latest results (unpublished results) indicate that at a
premotor phase (7–12months) when no loss of SNc DA neurons
is evident yet, c-rel /  mice display olfactory deficits, gut dys-
functions, and reduced DAT immunoreactivity in the striatum.
This disease progression mimics the pathological and clinical
progression observed in PD patients that at premotor stage of
the disease show constipation, hyposmia (85), and reduced DAT
imaging by PETor SPECT scan. These findings further strengthen
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the notion that c-rel /  mice represent an innovative disease
model suitable both for studies aimed at dissecting the mecha-
nisms of PD onset and to test novel therapeutic approaches for
intervention at the premotor stages of the disorder.
Conclusion
Although NF-κB factors are transcriptional regulators of inflam-
mation and apoptosis, their relevance in aging-related neurode-
generation is still underestimated.
Activation of RelA has been proposed to lead the systemic aging
process in mice (86, 87), being negligible in the hypothalamus of
young mice and progressively increasing, earlier in microglia and
later in neuronal cells, as the mice become older (12). The genetic
depletion of one allele of RelA attenuated the behavioral signs of
neurodegeneration and extended the healthspan in a progeroid
mouse model (13).
These stimulating results could be reread in the light of recent
evidence showing that protective versus harmful p50/RelA acti-
vation strongly depends on the acetylation state of RelA. Activa-
tion of RelA subunit displaying reduced grade of general acety-
lation, but site-specific acetylation of K310, triggers apoptotic
gene expression in brain ischemia. In the absence of such a mis-
match, the activation of RelA is neuroprotective, as observed in
preconditioning ischemia.
Whether a dysregulation of the RelA acetylation state is
also involved in normal aging, or just in pathological aging,
remains to be established. What seems promising is that aber-
rant RelA acetylation, more than RelA nuclear translocation,
can be a suitable target. It is corrected by the synergistic
association of HDAC inhibitors and resveratrol to produce
neuroprotection.
While evidence suggests that RelA activation marks physiolog-
ical elderly in mice, we show that the deficiency of c-Rel leads
to a parkinsonian phenotype with aging (10). The degeneration
of DA neurons in the SNc, the microglia activation and the α-
synuclein pathology are associated with development of an -
DOPA-responsive parkinsonism. Intriguingly, in the basal ganglia
of aged c-Rel deficient mice, but not in agedmatched controls, the
acetylation state of RelA was reminding the one observed in lethal
ischemia.
This body of evidence supports the premise that the balance
between c-Rel- and RelA-mediated transcription may be at the
crossroad between normal and pathological aging of the mammal
brain. A defect of c-Rel activity, associated with higher RelA
activation, reduces SNc resilience to aging hereby leading to a
late-onset form of parkinsonism. Validation of the impact of c-
Rel activity in PD onset and progression is now the challenge of
ongoing studies.
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